TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9170037
Drug: sprodiamide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sprodiamide injection
Study: 1492860
Drug: Dihydroergocristine (DHEC)
Normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine (DHEC) 3 ml drops (2 mg/ml)
Study: 1492860
Drug: Dihydroergocristine (DHEC)
Normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine (DHEC) single-dose bottle (6 mg)
Study: 27931302
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 microgram daily dose
Study: 27931302
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 microgram daily combined with LABA (formoterol)
Study: 27931302
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 microgram daily combined with LTRA (montelukast)
Study: 27931302
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 microgram daily dose
Study: 23183711
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bromocriptine and sulpiride
Study: 12456421
Drug: Ketamine 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 3.0 or 3.5 mg/kg with lidocaine spray
Study: 10479851
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 cc of physiological infusion administered in the same manner)
Study: 6958487
Drug: Becotide Nasal
Normalized name: BECOTIN CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Becotide Nasal (400 micrograms daily, administered four times a day)
Study: 26868369
Drug: Inhaled mometasone
Normalized name: mometasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled mometasone
Study: 19942107
Drug: Yoga sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga sessions lasting 60 min daily
Study: 19942107
Drug: Brief supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief supportive therapy once in 10 days
Study: 15782505
Drug: Neostigmine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.02 mg/kg) and atropine (0.01 mg/kg) infusion in group C and group D after neuromuscular recovery (T1/T(C)) reached 10%.
Study: 15782505
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) 30 mg/kg in saline intravenously within 5 min in group A and group C.
Study: 15782505
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion in group B and group D.
Study: 15782505
Drug: Neostigmine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine and atropine infusion in group C and group D.
Study: 8583661
Drug: Acetated Ringer
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer (AR) solution
Study: 8583661
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer (LR) solution
Study: 1681365
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of Ty21a vaccine
Study: 90214
Drug: Methadone (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (average 97 mg/day, range 30-130 mg)
Study: 90214
Drug: Placebo (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with gradual reduction of methadone at 1 mg/day)
Study: 31774956
Drug: Satralizumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satralizumab (120 mg, subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter)
Study: 17202432
Drug: Rotigotine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (2 mg/24 h titrated to 6 mg/24 h)
Study: 20887513
Drug: Fluoridin N5®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridin N5® (Fluoride gel; Voco‐GmbH, Cuxhaven, Germany)
Study: 3995960
Drug: 25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micrograms sulprostone gel
Study: 3569828
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms sulprostone gel
Study: 3569828
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms sulprostone gel
Study: 2750356
Drug: gel vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel vehicle tylose
Study: 17156852
Drug: Poor medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor medication adherence in the 30 days prior to the trial
Study: 9042987
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg daily (for unhealed or symptomatic patients at week 4)
Study: 26089641
Drug: Carvedilol sustained-release
Normalized name: carvedilol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol sustained-release (SR) formulation 8 mg
Study: 26089641
Drug: Carvedilol sustained-release
Normalized name: carvedilol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol sustained-release (SR) formulation 16 mg
Study: 26089641
Drug: Carvedilol sustained-release
Normalized name: carvedilol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol sustained-release (SR) formulation 32 mg
Study: 24238498
Drug: Baxter dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxter dialysis solution 6 L
Study: 24238498
Drug: Changfu dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changfu dialysis solution 8 L
Study: 24238498
Drug: Baxter dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxter dialysis solution 8 L
Study: 24238498
Drug: Changfu 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changfu 6 L vs 8 L
Study: 19933719
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (low to moderate doses)
Study: 29728515
Drug: End-of-Treatment PET
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-Treatment PET (EoT-PET)
Study: 26715701
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion analgesia
Study: 26715701
Drug: Intra-articular infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular infusion analgesia
Study: 19041835
Drug: Eplerenone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone with standard treatment
Study: 16439590
Drug: HiPro formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: HiPro formula (3.6 g/100 kcal)
Study: 16439590
Drug: RegPro formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: RegPro formula (3.0 g/100 kcal)
Study: 3900907
Drug: Calf lung
Normalized name: Calf lung surfactant extract (CLSE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf lung surfactant extract administered at birth
Study: 29100885
Drug: Inhaled 21%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled 21% oxygen (placebo) for 2 hours daily, twice weekly, for 12 weeks
Study: 26471344
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (HP; 1.7 g kg(‐1) per day; n=31)
Study: 26471344
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (NP; 0.9 g kg(‐1) per day; n=30)
Study: 12824094
Drug: Theaflavin-enriched green
Normalized name: theaflavin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theaflavin-enriched green tea extract (375 mg)
Study: 10638896
Drug: Mivacurium (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (0.2 mg/kg)
Study: 6321689
Drug: FACP/weekly doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FACP/weekly doxorubicin
Study: 30099212
Drug: NLC-based formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLC-based formulations
Study: 27042735
Drug: Seasonal inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal inactivated influenza vaccine without a lipid adjuvant
Study: 24796768
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g LT‐02
Study: 24796768
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g LT‐02
Study: 24796768
Drug: 3.2 g
Normalized name: OATMEAL 2.3 g in 113.2 g TOPICAL CREAM [EczeNil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 g LT‐02
Study: 23051558
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination (T80/H25)
Study: 15765326
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg initial IV injection, then 3 mg every 5 minutes)
Study: 11510921
Drug: Heparin coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin coated circuits combined with leukocyte filtration (group I)
Study: 9764623
Drug: oral water
Normalized name: Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral water
Study: 30015069
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention package including detection, treatment, and control of cardiovascular risk factors by nonphysician health workers, free dispensation of combination antihypertensive and cholesterol-lowering medications, and support from a treatment supporter.
Study: 20711439
Drug: Contrast therapy
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast therapy
Study: 21470279
Drug: 20% lipid/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% lipid/heparin infusion (LHI)
Study: 11106119
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 on days 1-8 plus cisplatin 100 mg/m2 (arm A)
Study: 11106119
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 on days 1-8 plus cisplatin 70 mg/m2 (arm B)
Study: 8225671
Drug: Streptokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase and adjunctive angioplasty
Study: 6873872
Drug: Intravenous cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cimetidine (300 mg)
Study: 6873872
Drug: Oral cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cimetidine (300 mg every 8 hours for 8 days)
Study: 27321122
Drug: ALA-DAG (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-DAG (2.5 g/d)
Study: 8871871
Drug: IFN 5
Normalized name: cpm/PE/DM/acetaminophen/guaifn 5 mg-10 mg-325 mg-200 mg (day)/2 mg-5 mg-10 mg-325 mg(night) ORAL TABLET, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN 5 MU, three times weekly by subcutaneous injection alone (n = 14)
Study: 1799151
Drug: Cefotiam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam (2 g intravenously with induction of anaesthesia)
Study: 6849542
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose corticosteroids (2 g methylprednisolone intravenously once a week plus 0.25 mg/kg prednisone orally daily)
Study: 6849542
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose corticosteroids (0.25 mg/kg prednisone orally daily)
Study: 31034349
Drug: In-office bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office bleaching with high hydrogen peroxide concentration (Opalescence Boost PF 40%, Ultradent) for 40 minutes in three sessions (first, eighth, and 15th days of treatment)
Study: 31034349
Drug: At-home bleaching
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home bleaching with low carbamide peroxide concentration (Opalescence PF 10%, Ultradent) for 60 minutes daily for 15 days
Study: 25521188
Drug: Dispersible tablet
Normalized name: Aspirin 75 mg orodispersible tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablet
Study: 16611285
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. for 7 days
Study: 8855804
Drug: T enanthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: T enanthate 200 mg im every 20 days
Study: 6441778
Drug: 3 types
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 types of hypocaloric parenteral nutrition (75 g/day amino acids with different carbohydrates: 120 g dextrose, 120 g or 200 g dextrose/fructose/xylitol)
Study: 6441778
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 75 g/day of dextrose
Study: 19295270
Drug: Oral cavity
Normalized name: INVEST ANTI-NEOPLASTIC DRUGS LIP,ORAL CAVITY AND PHARYNX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cavity care patient guidance including teaching good brushing methods, O'Leary's Plaque Control Record (PCR) as a cleanliness index, and Eilers' Oral Assessment Guide (OAG) as an overall index after April 2006
Study: 19295270
Drug: Oral cavity
Normalized name: INVEST ANTI-NEOPLASTIC DRUGS LIP,ORAL CAVITY AND PHARYNX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cavity care patient guidance
Study: 9617377
Drug: Optimal antiemetic
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal antiemetic prophylaxis for delayed emesis induced by moderately emetogenic chemotherapy
Study: 2453704
Drug: Allopurinol 250-500
Normalized name: allopurinol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 250-500 mg/m2 body surface
Study: 29653629
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline (100 mg once a day for 28 days)
Study: 306577
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline
Study: 23937708
Drug: Nightly sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly sildenafil (50 mg)
Study: 23937708
Drug: On-demand sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand sildenafil (50 mg)
Study: 16957147
Drug: Enoxaparin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.5 mg/kg)
Study: 18234466
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5000 IU)
Study: 16490582
Drug: Extended-release hydromorphone
Normalized name: hydromorphone Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release hydromorphone hydrochloride (ER hydromorphone HCl) administered every 24 hours
Study: 16490582
Drug: Immediate-release hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release hydromorphone hydrochloride (IR hydromorphone HCl) tablets as rescue medication
Study: 12746764
Drug: Intravenous diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diphenhydramine administration
Study: 12746764
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L-AMB) infusion
Study: 10952475
Drug: Zaleplon 20
Normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zaleplon 20 mg alone
Study: 15496221
Drug: Thioridazine 50
Normalized name: thioridazine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine 50 mg alone
Study: 10952475
Drug: Zaleplon 20
Normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zaleplon 20 mg and Thioridazine 50 mg coadministration
Study: 8337731
Drug: Intramuscular QN
Normalized name: QN-302
DrugBank: QN-302 (DB18156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular QN alone (quinine dihydrochloride 20 mg salt/kg as a loading dose, followed by 10 mg salt/kg 12 hourly for a total of 6 doses)
Study: 3806204
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (1-(2-chloroethyl)-1-nitrosourea, vincristine, and prednisone)
Study: 22360134
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) continuous regimen: 1,000 AU/week for the entire study period (Group 1)
Study: 8008325
Drug: Azithromycin, 1
Normalized name: Azithromycin, 1 g oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 1 g orally as one dose
Study: 8008325
Drug: Erythromycin, 500
Normalized name: Erythromycin, 500 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 500 mg orally four times a day for 7 days
Study: 5015048
Drug: Prednisolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (20 mg daily for one day before and two days after irradiation)
Study: 5015048
Drug: No preliminary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preliminary treatment (Control group)
Study: 22097198
Drug: Cardioplegic solution
Normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioplegic solution with Salvia miltiorrhizae (SM)
Study: 22097198
Drug: Cardioplegic solution
Normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioplegic solution without Salvia miltiorrhizae (Control)
Study: 19214920
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT) with human premixed insulin b.d. (n=20)
Study: 19214920
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy (ICT) with Lispro at meals and NPH at bedtime (n=24)
Study: 9817170
Drug: 4-1BB receptor
Normalized name: PD-L1/4-1BB bispecific antibody
DrugBank: ATG-101 (DB17162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-1BB receptor
Study: 2780057
Drug: Ketoprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (100 mg in 5 ml saline)
Study: 8942334
Drug: Saline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (5 ml)
Study: 31689320
Drug: Adhere4U mobile
Normalized name: CHAMAEMELUM NOBILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhere4U mobile medication manager application
Study: 26573447
Drug: Topical chamomile
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical chamomile oil, applied twice daily for 4 weeks
Study: 26573447
Drug: Placebo, applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, applied twice daily for 4 weeks
Study: 22958202
Drug: Short-acting insulin
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting insulin 4 U
Study: 14735861
Drug: Intrarectal lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal lidocaine, 20 mg (group 1)
Study: 8033498
Drug: Orlistat (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (30 to 1200 mg, three times a day for 9 to 10 days)
Study: 18156658
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (0.25 g.kg(‐1).h(‐1)) during hours 0-12 and 24-36 postexercise
Study: 15955653
Drug: NonTCA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NonTCA treatment
Study: 12196838
Drug: Ganciclovir (GCV)
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir (GCV) + Intravenous Immunoglobulin (IVIG)
Study: 9934915
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of intratracheal surfactant (80 mL/m2)
Study: 8689457
Drug: hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: hylan G-F 20 with NSAID continuation
Study: 8689457
Drug: hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: hylan G-F 20 alone (NSAID discontinuation)
Study: 375377
Drug: Cimetidine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (0.6 mg.kg‐1h‐1)
Study: 28633627
Drug: Motivational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motivational intervention (400 patients), delivered by a nurse trained by an expert psychologist, in 32 sessions (1 to 12 fortnightly, 13 to 32 monthly) on top of standard diet and exercise
Study: 22469604
Drug: Cyclamen europaeum
Normalized name: Alfalfa/Bogbean/Common Oat/Cyclamen Europaeum/Echinacea angustifoliae/Ginseng, American/Kali Phosphoricum 1 X/7.5 ML-0.3 X/2.5 ML-0.1 X/7.5 ML-0.6 X/2.5 ML-0.1 X/5 ML-0.1 X/5 ML-0.5 C/2.5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclamen europaeum nasal spray (CE) once daily for 15 days
Study: 22469604
Drug: Cyclamen europaeum
Normalized name: Alfalfa/Bogbean/Common Oat/Cyclamen Europaeum/Echinacea angustifoliae/Ginseng, American/Kali Phosphoricum 1 X/7.5 ML-0.3 X/2.5 ML-0.1 X/7.5 ML-0.6 X/2.5 ML-0.1 X/5 ML-0.1 X/5 ML-0.5 C/2.5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclamen europaeum nasal spray (CE)
Study: 18075447
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of prednisone for 5 days preoperatively and 9 days postoperatively
Study: 12361815
Drug: Caspofungin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (50 mg) intravenously once daily for 7 to 21 days
Study: 12361815
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg) intravenously once daily for 7 to 21 days
Study: 6666227
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ISDN sustained-release, three times a day